Various literatures are reported on the versatility of pyridazinone molecules, an article was selected with reported IC50. 20 compounds (S1-S20) were selected for combined and stepwise in silico studies on pyridazinone moieties in the form of GQSAR, pharmacophore matching and molecular docking studies. These studies revealed important physicochemical properties of pyridazinones responsible for various biological activities. Group based QSAR (GQSAR) on COX-2 was carried out and 2 best models were studied. Pharm Mapper webserver was used for in silico reverse target screening to find out potential therapeutic targets for pyridazinones. The targets identified using in-silico method like Tyrosine phosphatases (PDB ID- 1NWL), Sorbitol dehydrogen...
In the present study, the affinity of pyridazine derivatives for the most promising antiparkinsonian...
The main objective present research work to synthesis, characterization and biological evaluation of...
Aimed to elaborate new group of protein kinase inhibitors we conducted receptor-based screening (doc...
The designing and synthesis of selected 6-(4-methylphenyl)-4,5-dihydropyridazin-3(2H)-one, 6-(4-benz...
We report here in silico repurposing studies on 52 new pyridazinone-based small-molecules through in...
Persistent inflammation contributes to a number of diseases; therefore, control of the inflammatory ...
A series of new pyridazin-3(2H)-one derivatives (3 and 4) were evaluated for their in vitro affinity...
A series of new pyridazin-3(2H)-one derivatives (3 and 4) were evaluated for their in vitro affinity...
International audienceCyclic nucleotide phosphodiesterase type 4 (PDE4), that controls intracellular...
A series of heterocyclic compounds incorporating pyridazine moiety were for diverse biological activ...
By following a multitarget ligand design approach, a library of 47 compounds was prepared, and they ...
<div><p>PDE3s belong to the phosphodiesterases family, where the PDE3A isoform is the major subtype ...
The pyridazine moiety is an important structural feature of various pharmacological active compounds...
PDE3s belong to the phosphodiesterases family, where the PDE3A isoform is the major subtype in plate...
Molecular docking is the identification of ligand’s correct binding geometry i.e pose in the binding...
In the present study, the affinity of pyridazine derivatives for the most promising antiparkinsonian...
The main objective present research work to synthesis, characterization and biological evaluation of...
Aimed to elaborate new group of protein kinase inhibitors we conducted receptor-based screening (doc...
The designing and synthesis of selected 6-(4-methylphenyl)-4,5-dihydropyridazin-3(2H)-one, 6-(4-benz...
We report here in silico repurposing studies on 52 new pyridazinone-based small-molecules through in...
Persistent inflammation contributes to a number of diseases; therefore, control of the inflammatory ...
A series of new pyridazin-3(2H)-one derivatives (3 and 4) were evaluated for their in vitro affinity...
A series of new pyridazin-3(2H)-one derivatives (3 and 4) were evaluated for their in vitro affinity...
International audienceCyclic nucleotide phosphodiesterase type 4 (PDE4), that controls intracellular...
A series of heterocyclic compounds incorporating pyridazine moiety were for diverse biological activ...
By following a multitarget ligand design approach, a library of 47 compounds was prepared, and they ...
<div><p>PDE3s belong to the phosphodiesterases family, where the PDE3A isoform is the major subtype ...
The pyridazine moiety is an important structural feature of various pharmacological active compounds...
PDE3s belong to the phosphodiesterases family, where the PDE3A isoform is the major subtype in plate...
Molecular docking is the identification of ligand’s correct binding geometry i.e pose in the binding...
In the present study, the affinity of pyridazine derivatives for the most promising antiparkinsonian...
The main objective present research work to synthesis, characterization and biological evaluation of...
Aimed to elaborate new group of protein kinase inhibitors we conducted receptor-based screening (doc...